EUVIMEDEUVIMED entdecken
Crossref

Serologic reactivity of unidentified specificity in antenatal testing and hemolytic disease of the fetus and newborn: The BEST collaborative study

Wen Lu iD, Alyssa Ziman iD, Matthew T S Yan iD, Allison Waters iD, Mrigender Singh Virk iD, Ann Tran, Hongying Tang, Andrew W Shih iD, Edel Scally, Jay S Raval, Suchi Pandey iD, Monica B Pagano iD und 9 weitere

Transfusion · 2023

DOI: 10.1111/trf.17276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2023. Verfasst von Wen Lu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Erythroblastosis, Fetal, Blood Group Antigens. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical significance of serologic reactivity of unidentified specificity (SRUS) in pregnancy is not clear based on available literature. The aim of this study is to determine if SRUS is associated with hemolytic disease of the fetus and newborn (HDFN). Study Design and Methods Retrospective data were collected from eight institutions over an 11‐year study period (2010–2020), when available (5/8 sites). The outcome of the pregnancies with SRUS—no, mild, moderate, or severe HDFN—was determined.

Results

SRUS was demonstrated in 589 pregnancies. After excluding those with incomplete data, a total of 284 pregnancies were included in the primary HDFN outcome analysis. SRUS was detected in 124 (44%) pregnancies in isolation, and none were affected by HDFN. Of 41 pregnancies with SRUS and ABO incompatibility, 37 (90%) were unaffected, and 4 (10%) were associated with mild HDFN. Of 98 pregnancies with SRUS and concurrent identifiable antibody reactivity(s), 80 (81%) were unaffected, and 19 (19%) were associated with mild to severe HDFN. There was 1 case of mild HDFN and 1 case of severe HDFN in the 21 pregnancies with SRUS, ABO incompatibility, and concurrent identifiable antibody reactivity(s), and 19 (90%) were unaffected by HDFN. Among all patients with repeat testing, newly identified alloantibodies or other antibodies were identified in 63 of 212 (30%) patients. Although most were not clinically significant, on occasion SRUS preceded clinically significant antibody(s) associated with HDFN (3%, 5/188).

Conclusion

The antenatal serologic finding of SRUS in isolation is not associated with HDFN but may precede clinically significant antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erythroblastosis, FetalBlood Group AntigensInfant, NewbornHumansFemalePregnancyRetrospective StudiesIsoantibodiesFetus

Stichwörter der Autor:innen

HDFNantenatalantibody screennonspecific reactivitypregnancy

Substanzen

Blood Group AntigensIsoantibodies

Autor:innen und Institutionen

  • Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Wing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Canadian Blood Services, Vancouver, British Columbia, Canada.
  • Irish Blood Transfusion Service, Dublin, Ireland.
  • Transfusion Medicine Service, Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Wen Lu, Alyssa Ziman, Matthew T S Yan, Allison Waters, Mrigender Singh Virk, Andrew W Shih, Suchi Pandey, Monica B Pagano, Hua Shan, Mark Yazer

Zitieren

APA

Lu, W., Ziman, A., Yan, M. T. S., Waters, A., Virk, M. S., Tran, A., Tang, H., Shih, A. W., Scally, E., Raval, J. S., Pandey, S., Pagano, M. B., Shan, H., Moore, C., Morrison, D., Cormack, O., Fitzgerald, J., Duncan, J., Corean, J., …, & Yazer, M. (2023). Serologic reactivity of unidentified specificity in antenatal testing and hemolytic disease of the fetus and newborn: The BEST collaborative study. Transfusion. https://doi.org/10.1111/trf.17276

Vancouver

Lu W, Ziman A, Yan MTS, Waters A, Virk MS, Tran A, et al. Serologic reactivity of unidentified specificity in antenatal testing and hemolytic disease of the fetus and newborn: The BEST collaborative study. Transfusion. 2023. doi:10.1111/trf.17276

BibTeX
@article{Lu2023,
  author = {Lu, Wen and Ziman, Alyssa and Yan, Matthew T S and Waters, Allison and Virk, Mrigender Singh and Tran, Ann and Tang, Hongying and Shih, Andrew W and Scally, Edel and Raval, Jay S and Pandey, Suchi and Pagano, Monica B and Shan, Hua and Moore, Carmel and Morrison, Douglas and Cormack, Orla and Fitzgerald, Joan and Duncan, Jennifer and Corean, Jessica and Clarke, Gwen and Yazer, Mark},
  title = {Serologic reactivity of unidentified specificity in antenatal testing and hemolytic disease of the fetus and newborn: The BEST collaborative study},
  journal = {Transfusion},
  year = {2023},
  doi = {10.1111/trf.17276}
}
Kostenlos starten →